Christopher Paul German Sells 2,069 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) CAO Christopher Paul German sold 2,069 shares of the business's stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $67.19, for a total transaction of $139,016.11. Following the completion of the sale, the chief accounting officer now directly owns 1,889 shares of the company's stock, valued at approximately $126,921.91. The trade was a 52.27% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Christopher Paul German also recently made the following trade(s):

• On Friday, March 21st, Christopher Paul German sold 344 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $54.23, for a total value of $18,655.12.

Rhythm Pharmaceuticals Stock Up 1.1%

Shares of RYTM stock traded up $0.70 during mid-day trading on Friday, reaching $63.72. The company's stock had a trading volume of 249,461 shares, compared to its average volume of 556,993. The firm has a market capitalization of $4.05 billion, a PE ratio of -14.71 and a beta of 2.30. The company's 50 day simple moving average is $61.97 and its 200-day simple moving average is $57.97. Rhythm Pharmaceuticals, Inc. has a 12-month low of $39.46 and a 12-month high of $69.89.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.12). The firm had revenue of $37.72 million for the quarter, compared to analysts' expectations of $40.43 million. Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The company's revenue for the quarter was up 25.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($2.35) EPS. As a group, research analysts anticipate that Rhythm Pharmaceuticals, Inc. will post -4.32 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on RYTM. Needham & Company LLC boosted their price target on shares of Rhythm Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a research report on Wednesday, May 7th. Bank of America raised shares of Rhythm Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $63.00 price objective for the company in a report on Monday, April 7th. Canaccord Genuity Group raised their price target on shares of Rhythm Pharmaceuticals from $81.00 to $92.00 and gave the stock a "buy" rating in a report on Tuesday, April 8th. HC Wainwright reiterated a "buy" rating and issued a $80.00 price objective (up from $70.00) on shares of Rhythm Pharmaceuticals in a report on Tuesday, April 8th. Finally, Stifel Nicolaus raised their target price on Rhythm Pharmaceuticals from $78.00 to $94.00 and gave the stock a "buy" rating in a research note on Thursday, May 29th. Thirteen analysts have rated the stock with a buy rating, According to MarketBeat.com, Rhythm Pharmaceuticals has a consensus rating of "Buy" and an average price target of $76.62.

Institutional Trading of Rhythm Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. First Trust Advisors LP grew its holdings in Rhythm Pharmaceuticals by 67.2% during the 4th quarter. First Trust Advisors LP now owns 118,337 shares of the company's stock worth $6,625,000 after acquiring an additional 47,575 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in Rhythm Pharmaceuticals during the 4th quarter worth approximately $521,000. SBI Securities Co. Ltd. acquired a new position in shares of Rhythm Pharmaceuticals in the 4th quarter worth approximately $37,000. BNP Paribas Financial Markets raised its position in shares of Rhythm Pharmaceuticals by 491.0% during the 4th quarter. BNP Paribas Financial Markets now owns 85,249 shares of the company's stock valued at $4,772,000 after acquiring an additional 70,824 shares in the last quarter. Finally, Teacher Retirement System of Texas lifted its stake in Rhythm Pharmaceuticals by 18.5% during the fourth quarter. Teacher Retirement System of Texas now owns 13,586 shares of the company's stock worth $761,000 after purchasing an additional 2,117 shares during the last quarter.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.